AI-Delivered Short Video Cognitive Behavioral Therapy for Type 2 Diabetes Mellitus – A Randomized Controlled Trial Protocol
- 1Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, People’s Republic of China
- 2Department of Endocrinology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, 211100, People’s Republic of China
Abstract
Background: This article presents a protocol for a randomized, controlled, multicenter trial that aims to evaluate whether the cognitive behavioral therapy (CBT) based on artificial intelligence (AI) short video push technology can improve glycemic control in patients with type 2 diabetes mellitus (T2DM) more effectively than traditional standard care. CBT has been shown to improve glycemic control in patients with T2DM. To help T2DM patients have and preserve behavioral changes for a long time, we have developed a self-management application TANKON. Patients can receive CBT of diabetes-related knowledge and skills by watching different short videos automatically played in the application, and the orders and content of short videos are precisely calculated based on AI technology.
Methods: This is a non-blinded, multicenter, parallel-group, randomized controlled trial with 1:1 equal randomization. A total of 298 participants (149 per group) will be enrolled from seven endocrinology departments across general hospitals in China. The intervention group (n = 149) will receive CBT via the TANKON app, an AI-powered platform that automatically delivers short educational videos. The control group (n = 149) will receive care-as-usual. In the following 12-week follow-up, the patients in the intervention group will choose to prolong or discontinue the use of the application. The primary endpoint is the difference in hemoglobin A1c (HbA1c) change from baseline to 12 weeks for the intervention group compared with those assigned to the control group. Safety assessment includes hypoglycemia events and other adverse events.
Conclusion: This trial evaluates CBT based on AI short video push technology which has the potential to provide a scalable treatment option for patients with T2DM.
Trial Registration: Trial-ID: ChiCTR2400080050, registration date: 18 January 2024 (https://www.chictr.org.cn/showproj.html?proj=216374).
Related
- Intensive cognitive behavioral therapy for obsessive-compulsive disorder: a meta-analysis of randomized controlled trials
- Feasibility of a Co-Designed Personalized Cognitive Reablement Program Delivered via Digital Voice Assistants for Older Adults Living With Early-Stage Dementia or Mild Cognitive Impairment: Pilot Randomized Controlled Trial.
- Electroacupuncture Combined with Cognitive Behavioral Therapy for Insomnia Alleviates Insomnia-Anxiety Comorbidity in Gynecological Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial.
- The Impact of Mindfulness as a Session‐Introduction on Symptoms and Alliance in Individual Cognitive‐Behavioral Therapy With Children and Adolescents: A Randomized Controlled Trial
- Transdiagnostic metacognitive therapy compared to disorder-specific cognitive behavioral therapy for anxiety disorders: a study protocol for a randomized controlled superiority trial
BibTeX
@article{zhao2026aidelivered,
title = {{AI-Delivered Short Video Cognitive Behavioral Therapy for Type 2 Diabetes Mellitus – A Randomized Controlled Trial Protocol}},
author = {Yijing Zhao and Su Wang and Yu Yang and Wen Cao and Kun Chen and Jie Liu and Chao Liu and Kun Wang},
journal = {Diabetes, Metabolic Syndrome and Obesity},
year = {2026},
month = oct,
doi = {10.2147/dmso.s616432},
url = {https://doi.org/10.2147/dmso.s616432},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - AI-Delivered Short Video Cognitive Behavioral Therapy for Type 2 Diabetes Mellitus – A Randomized Controlled Trial Protocol
AU - Yijing Zhao
AU - Su Wang
AU - Yu Yang
AU - Wen Cao
AU - Kun Chen
AU - Jie Liu
AU - Chao Liu
AU - Kun Wang
PY - 2026
DA - 2026/10/31
JO - Diabetes, Metabolic Syndrome and Obesity
DO - 10.2147/dmso.s616432
UR - https://doi.org/10.2147/dmso.s616432
AB - Background: This article presents a protocol for a randomized, controlled, multicenter trial that aims to evaluate whether the cognitive behavioral therapy (CBT) based on artificial intelligence (AI) short video push technology can improve glycemic control in patients with type 2 diabetes mellitus (T2DM) more effectively than traditional standard care. CBT has been shown to improve glycemic control in patients with T2DM. To help T2DM patients have and preserve behavioral changes for a long time, we have developed a self-management application TANKON. Patients can receive CBT of diabetes-related knowledge and skills by watching different short videos automatically played in the application, and the orders and content of short videos are precisely calculated based on AI technology. Methods: This is a non-blinded, multicenter, parallel-group, randomized controlled trial with 1:1 equal randomization. A total of 298 participants (149 per group) will be enrolled from seven endocrinology departments across general hospitals in China. The intervention group (n = 149) will receive CBT via the TANKON app, an AI-powered platform that automatically delivers short educational videos. The control group (n = 149) will receive care-as-usual. In the following 12-week follow-up, the patients in the intervention group will choose to prolong or discontinue the use of the application. The primary endpoint is the difference in hemoglobin A1c (HbA1c) change from baseline to 12 weeks for the intervention group compared with those assigned to the control group. Safety assessment includes hypoglycemia events and other adverse events. Conclusion: This trial evaluates CBT based on AI short video push technology which has the potential to provide a scalable treatment option for patients with T2DM. Trial Registration: Trial-ID: ChiCTR2400080050, registration date: 18 January 2024 (https://www.chictr.org.cn/showproj.html?proj=216374).
SN - 1178-7007
ER -